Sequential treatment with targeted and immune checkpoint inhibitor therapies in patients with BRAF positive metastatic melanoma: Real-world data.

被引：0
|
作者：
Cybulska-Stopa, Bozena
Czarnecka, Anna Malgorzata
Ostaszewski, Krzysztof
Piejko, Karolina
Zietek, Marcin
Dziura, Robert
Rutkowska, Ewa
Galus, Lukasz
Ziolkowska, Barbara
Kempa-Kaminska, Natasza
Seredynska, Joanna
Kamycka, Agnieszka
Bal, Wieslaw
Surus-Hyla, Anna
Switaj, Tomasz
Rogala, Pawel
Kaminska-Winciorek, Grazyna
Suwinski, Rafal
Mackiewicz, Jacek
Rutkowski, Piotr
机构：
[1] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Clin Oncol, Cracow Branch, Krakow, Poland
[2] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland
[3] Wroclaw Med Univ, Dept Oncol, Wroclaw, Poland
[4] Wroclaw Comprehens Canc Ctr, Dept Surg Oncol, Wroclaw, Poland
[5] Holy Cross Canc Ctr, Dept Clin Oncol, Kielce, Poland
[6] Univ Med Sci, Dept Med & Expt Oncol, Heliodor Swiecicki Clin Hosp, Poznan, Poland
[7] Maria Sklodowska Curie Natl Res Inst Oncol, Clin Radiotherapy & Chemotherapy 2, Gliwice Branch, Gliwice, Poland
[8] Wroclaw Comprehens Canc Ctr, Dept Clin Oncol, Wroclaw, Poland
[9] Podkarpacki Centrum Onkol Rzeszowie, Rzeszow, Poland
[10] Gliwice Oncol Inst, Gliwice, Poland
[11] Minist Interior & Adm Hosp, Clin Dept Oncol & Immuno Oncol, Warmian Masurian Canc Ctr, Olsztyn, Poland
[12] Maria Sklodowska Curie Natl Res Inst Oncol, Gliwice Branch, Dept Bone Marrow Transplantat & Onco Hematol, Skin Canc & Melanoma Team, Gliwice, Poland
[13] Greater Poland Canc Ctr, Dept Diagnost & Canc Immunol, Poznan, Poland
[14] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21539
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real-world data in the era of immune checkpoint inhibitors
    Narita, Yukiya
    ANNALS OF ONCOLOGY, 2021, 32 : S250 - S250
  • [32] Real-world evaluation of the efficacy of immune checkpoint inhibitors in the treatment of metastatic breast cancer
    Qian, Xiaoyan
    Tao, Yunxia
    Chen, Haizhu
    Li, Xin
    Wang, Yaqin
    Xu, Xiaoming
    Li, Shuo
    Chen, Haoyu
    Cang, Shundong
    Liu, Yang
    ONCOLOGY LETTERS, 2025, 29 (01)
  • [33] BRAF TARGETED THERAPIES FOR THE TREATMENT OF METASTATIC MELANOMA: A COST-EFFECTIVENESS ANALYSIS
    Shih, V
    ten Ham, R. M. T.
    Bui, C. T.
    Tran, D. N.
    Wilson, L. S.
    VALUE IN HEALTH, 2014, 17 (03) : A84 - A84
  • [34] Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era
    Hiroki Ishihara
    Yuki Nemoto
    Kazutaka Nakamura
    Hidekazu Tachibana
    Hironori Fukuda
    Kazuhiko Yoshida
    Hirohito Kobayashi
    Junpei Iizuka
    Hiroaki Shimmura
    Yasunobu Hashimoto
    Kazunari Tanabe
    Tsunenori Kondo
    Toshio Takagi
    Targeted Oncology, 2022, 17 : 307 - 319
  • [35] New targeted therapies in the treatment of patients with metastatic melanoma
    Mackiewicz, Jacek
    Kwinta, Lukasz
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2010, 14 (01): : 15 - 22
  • [36] The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study
    Lev-Ari, Shaked
    Serzan, Michael
    Wu, Tianmin
    Ip, Andrew
    Pascual, Lauren
    Sinclaire, Brittany
    Adams, Shari
    Marafelias, Michael
    Ayyagari, Lakshmi
    Gill, Sarvarinder K.
    Ma, Barbara
    Zaemes, Jacob P.
    Della Pia, Alexandra
    Alaoui, Adil
    Madhavan, Subha
    Belouali, Anas
    Pecora, Andrew
    Ahn, Jaeil
    Atkins, Michael B.
    Shah, Neil J.
    CANCER, 2023, 129 (12) : 1885 - 1894
  • [37] Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era
    Ishihara, Hiroki
    Nemoto, Yuki
    Nakamura, Kazutaka
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Tanabe, Kazunari
    Kondo, Tsunenori
    Takagi, Toshio
    TARGETED ONCOLOGY, 2022, 17 (03) : 307 - 319
  • [38] Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy
    Atkins, Michael B.
    Julian, Cristina
    Secrest, Matthew H.
    Lee, Janet
    Abajo-Guijarro, Ana M.
    McKenna, Edward
    FUTURE ONCOLOGY, 2022, 18 (18) : 2233 - 2245
  • [39] Real-world evidence of the impact of prior antibiotic exposure on immune checkpoint inhibitor outcomes in patients with metastatic urothelial cancer
    Hoffman-Censits, Jean H.
    Harshman, Lauren Christine
    Metcalf, Meredith
    Abou Alaiwi, Sarah
    Meyer, Craig S.
    Yang, Erru
    Satram, Sacha
    Ogale, Sarika
    Faber, Kathleene
    Ma, Esprit
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [40] Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
    Teresa Kim
    Rodabe NAmaria
    Christine Spencer
    Alexandre Reuben
    Zachary ACooper
    Jennifer AWargo
    Cancer Biology & Medicine, 2014, 11 (04) : 237 - 246+213
12345